©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 14, 2015; 21(10): 2871-2874
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.2871
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.2871
Targeted therapy in first line treatment of RAS wild type colorectal cancer
Vincenzo Formica, Mario Roselli, Medical Oncology Unit, “Tor Vergata” University Hospital, 00133 Rome, Italy
Author contributions: Formica V wrote the paper; and Roselli M revised the scientific content of the paper
Conflict-of-interest: Authors have no conflict of interest to declare related to the present article.
Correspondence to: Vincenzo Formica, MD, PhD, Medical Oncology Unit, Department of Internal Medicine, “Tor Vergata” University Hospital, Viale Oxford 81, 00133 Rome, Italy. vincenzo.formica@uniroma2.it
Telephone: +39-6-20908190 Fax: +39-6-20903806
Received: November 17, 2014
Peer-review started: November 18, 2014
First decision: December 26, 2014
Revised: January 8, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: March 14, 2015
Processing time: 118 Days and 20.1 Hours
Peer-review started: November 18, 2014
First decision: December 26, 2014
Revised: January 8, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: March 14, 2015
Processing time: 118 Days and 20.1 Hours
Core Tip
Core tip: Three new randomized head-to-head trials have explored the use of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor targeted agents in chemotherapy-naïve metastatic colorectal cancer patients not carrying activating mutations of RAS proteins.